Reducing ovarian cancer death rates through screening

Cancer

Volumn 117, Issue 3, 2011, Pages 449-450

  Hartge, Patricia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

BREAST CANCER 1 GENE; BREAST CANCER 2 GENE; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; ECHOGRAPHY; EDITORIAL; FALSE POSITIVE RESULT; HIGH RISK POPULATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR GENE; WOMEN'S HEALTH;

CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; OVARIAN NEOPLASMS; RISK; SURVIVAL RATE; TIME FACTORS;

EID: 79251529883     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25622     Document Type: Editorial

References (4)

1. Havrilesky LJ, Sanders GD, Kulasingam S, et al. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer. 2010; 117: 545-53.
2. Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010; 102: 26-38.
3. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10: 327-340.
4. Partridge E, Kreimer AR, Greenlee RT, et al. Results from 4 rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009; 113: 775-882.